178 related articles for article (PubMed ID: 9625578)
1. Oral L-glutamine therapy for sickle cell anemia: I. Subjective clinical improvement and favorable change in red cell NAD redox potential.
Niihara Y; Zerez CR; Akiyama DS; Tanaka KR
Am J Hematol; 1998 Jun; 58(2):117-21. PubMed ID: 9625578
[TBL] [Abstract][Full Text] [Related]
2. L-Glutamine in sickle cell disease.
Cox SE; Hart E; Kirkham FJ; Stotesbury H
Drugs Today (Barc); 2020 Apr; 56(4):257-268. PubMed ID: 32309821
[TBL] [Abstract][Full Text] [Related]
3. Decreased erythrocyte nicotinamide adenine dinucleotide redox potential and abnormal pyridine nucleotide content in sickle cell disease.
Zerez CR; Lachant NA; Lee SJ; Tanaka KR
Blood; 1988 Feb; 71(2):512-5. PubMed ID: 3337912
[TBL] [Abstract][Full Text] [Related]
4. Relationship between the nicotinamide adenine dinucleotide redox potential and the 2,3-diphosphoglycerate content in the erythrocyte in sickle cell disease.
Lachant NA; Zerez CR; Tanaka KR
Br J Haematol; 1989 Jun; 72(2):265-71. PubMed ID: 2757969
[TBL] [Abstract][Full Text] [Related]
5. A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Niihara Y; Miller ST; Kanter J; Lanzkron S; Smith WR; Hsu LL; Gordeuk VR; Viswanathan K; Sarnaik S; Osunkwo I; Guillaume E; Sadanandan S; Sieger L; Lasky JL; Panosyan EH; Blake OA; New TN; Bellevue R; Tran LT; Razon RL; Stark CW; Neumayr LD; Vichinsky EP;
N Engl J Med; 2018 Jul; 379(3):226-235. PubMed ID: 30021096
[TBL] [Abstract][Full Text] [Related]
6. Impaired erythrocyte methemoglobin reduction in sickle cell disease: dependence of methemoglobin reduction on reduced nicotinamide adenine dinucleotide content.
Zerez CR; Lachant NA; Tanaka KR
Blood; 1990 Sep; 76(5):1008-14. PubMed ID: 2393709
[TBL] [Abstract][Full Text] [Related]
7. Increased red cell glutamine availability in sickle cell anemia: demonstration of increased active transport, affinity, and increased glutamate level in intact red cells.
Niihara Y; Zerez CR; Akiyama DS; Tanaka KR
J Lab Clin Med; 1997 Jul; 130(1):83-90. PubMed ID: 9242370
[TBL] [Abstract][Full Text] [Related]
8. L-glutamine for sickle cell disease: more than reducing redox.
Jafri F; Seong G; Jang T; Cimpeanu E; Poplawska M; Dutta D; Lim SH
Ann Hematol; 2022 Aug; 101(8):1645-1654. PubMed ID: 35568758
[TBL] [Abstract][Full Text] [Related]
9. Pyridine nucleotide redox potential in erythrocytes of saudi subjects with sickle cell disease.
Al-Ali AK
Acta Haematol; 2002; 108(1):19-22. PubMed ID: 12145462
[TBL] [Abstract][Full Text] [Related]
10. L-glutamine therapy reduces endothelial adhesion of sickle red blood cells to human umbilical vein endothelial cells.
Niihara Y; Matsui NM; Shen YM; Akiyama DA; Johnson CS; Sunga MA; Magpayo J; Embury SH; Kalra VK; Cho SH; Tanaka KR
BMC Blood Disord; 2005 Jul; 5():4. PubMed ID: 16042803
[TBL] [Abstract][Full Text] [Related]
11. Hydroxyurea therapy modulates sickle cell anemia red blood cell physiology: Impact on RBC deformability, oxidative stress, nitrite levels and nitric oxide synthase signalling pathway.
Nader E; Grau M; Fort R; Collins B; Cannas G; Gauthier A; Walpurgis K; Martin C; Bloch W; Poutrel S; Hot A; Renoux C; Thevis M; Joly P; Romana M; Guillot N; Connes P
Nitric Oxide; 2018 Dec; 81():28-35. PubMed ID: 30342855
[TBL] [Abstract][Full Text] [Related]
12. Oral glutamine supplementation decreases resting energy expenditure in children and adolescents with sickle cell anemia.
Williams R; Olivi S; Li CS; Storm M; Cremer L; Mackert P; Wang W
J Pediatr Hematol Oncol; 2004 Oct; 26(10):619-25. PubMed ID: 15454831
[TBL] [Abstract][Full Text] [Related]
13. Desferrioxamine (DFO) conjugated with starch decreases NAD redox potential of intact red blood cells (RBC): evidence for DFO as an extracellular inducer of oxidant stress in RBC.
Niihara Y; Shalev O; Hebbel RP; Wu H; Tu A; Akiyama DS; Tanaka KR
Am J Hematol; 2000 Dec; 65(4):281-4. PubMed ID: 11074553
[TBL] [Abstract][Full Text] [Related]
14. l-Glutamine for sickle cell anemia: more questions than answers.
Quinn CT
Blood; 2018 Aug; 132(7):689-693. PubMed ID: 29895661
[TBL] [Abstract][Full Text] [Related]
15. Hydroxyurea and erythropoietin therapy in sickle cell anemia.
Goldberg MA; Brugnara C; Dover GJ; Schapira L; Lacroix L; Bunn HF
Semin Oncol; 1992 Jun; 19(3 Suppl 9):74-81. PubMed ID: 1379376
[TBL] [Abstract][Full Text] [Related]
16. Implications for the metabolic fate of oral glutamine supplementation within plasma and erythrocytes of patients with sickle cell disease: A pharmacokinetics study.
Morris CR; Kuypers FA; Hagar R; Larkin S; Lavrisha L; Saulys A; Vichinsky EP; Suh JH
Complement Ther Med; 2022 Mar; 64():102803. PubMed ID: 35032556
[TBL] [Abstract][Full Text] [Related]
17. The effects of glutamine supplementation on markers of apoptosis and autophagy in sickle cell disease peripheral blood mononuclear cells.
Walter PB; Hohman LS; Rokeby A; Lum JJ; Hagar R; Lavrisha L; Saulys A; Kuypers FA; Vichinsky E; Morris CR
Complement Ther Med; 2022 Nov; 70():102856. PubMed ID: 35843474
[TBL] [Abstract][Full Text] [Related]
18. Desferrioxamine decreases NAD redox potential of intact red blood cells: evidence for desferrioxamine as an inducer of oxidant stress in red blood cells.
Niihara Y; Ge J; Shalev O; Wu H; Tu A; Tanaka KR
BMC Clin Pharmacol; 2002 Oct; 2():8. PubMed ID: 12398791
[TBL] [Abstract][Full Text] [Related]
19. Extraction and Quantitation of Nicotinamide Adenine Dinucleotide Redox Cofactors.
Lu W; Wang L; Chen L; Hui S; Rabinowitz JD
Antioxid Redox Signal; 2018 Jan; 28(3):167-179. PubMed ID: 28497978
[TBL] [Abstract][Full Text] [Related]
20. Association and redox properties of the putidaredoxin reductase-nicotinamide adenine dinucleotide complex.
Reipa V; Holden MJ; Vilker VL
Biochemistry; 2007 Nov; 46(45):13235-44. PubMed ID: 17941648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
